Real-world data show DoxyPEP implementation among PrEP users significantly reduces the incidence of chlamydia and syphilis.

In the first-ever efficacy trial of antiretroviral-based pre-exposure prophylaxis, once-daily oral tenofovir significantly reduced the risk for HIV acquisition among men who have sex with men. The use ...

PLANO, Texas, Jan. 22, 2026 /PRNewswire/ -- Q Care Plus, a telehealth provider known for its leadership in providing HIV ...

MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (PFE) and Shionogi as shareholders, is pleased to ...

A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

Pre-exposure prophylaxis clinical trials of a 3-dose regimen of Verorab® followed by a booster dose at 1 year in adults and children achieved an adequate immune response.1 Of those who had a booster ...

In their research article published in Eurosurveillance, von Schreeb et al. challenge existing assumptions regarding the relationship between the use of HIV pre-exposure prophylaxis (PrEP) and the ...

Please provide your email address to receive an email when new articles are posted on . The Infectious Disease Society of America suggests that immunocompromised patients take the COVID-19 prevention ...